To the full analysis
Agios Pharmaceuticals stock: growth
AGIOAgios Pharmaceuticals reported $54.03M in revenue for fiscal 2025, up 48% on the prior year.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.7%
per year from 2011 to 2025, per share 0%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | no data | −0.9% | 6.7% |
| Revenue per share | no data | −5.1% | 0.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $21.84M | −$23.71M | −$17.13M |
| 2012 | $25.11M | −$20.1M | −$51.02M |
| 2013 | $25.55M | −$39.41M | −$57.69M |
| 2014 | $65.36M | −$53.5M | −$61.57M |
| 2015 | $59.12M | −$117.73M | −$97.11M |
| 2016 | $69.89M | −$198.47M | $28.65M |
| 2017 | $43.01M | −$314.67M | −$289.86M |
| 2018 | $94.39M | −$346.03M | −$311.41M |
| 2019 | $117.91M | −$411.47M | −$382.79M |
| 2020 | $0 | −$327.37M | −$304.87M |
| 2021 | $0 | $1.6B | −$413.06M |
| 2022 | $14.24M | −$231.8M | −$314.36M |
| 2023 | $26.82M | −$352.09M | −$297.06M |
| 2024 | $36.5M | $673.73M | −$391.53M |
| 2025 | $54.03M | −$412.78M | −$377.29M |
Revenue by region
Where Agios Pharmaceuticals, Inc. generates its revenue.
- United States$49.2M91%
- Outside the US$4.9M9%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $49.17M | 91% |
| Outside the US | $4.86M | 9% |
| Total revenue | $54.03M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.